等待开盘 06-26 09:30:00 美东时间
+0.370
+2.52%
Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic's Phase 3 trials in 2026.
05-27 18:17
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32
Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.
04-18 02:20
D. Boral Capital analyst Jason Kolbert downgrades Immunic (NASDAQ:IMUX) from Buy to Hold.
04-15 20:24
Immunic Inc (NASDAQ:IMUX) is surging Friday after the late‑stage biotech announced a private placement of up to $400 million.
02-14 00:25
EF Hutton analyst Jason Kolbert initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $17.
2024-09-16 20:25
05:47 AM EDT, 08/27/2024 (MT Newswires) -- Immunic (IMUX) has an average outperform rating and a price target range of $5 to $28, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Eu...
2024-08-27 17:47